These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9724072)

  • 41. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.
    Endrikat J; Jaques MA; Mayerhofer M; Pelissier C; Müller U; Düsterberg B
    Contraception; 1995 Oct; 52(4):229-35. PubMed ID: 8605781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
    Hammond GL; Bocchinfuso WP; Orava M; Smith CL; van den Ende A; van Enk A
    Contraception; 1994 Oct; 50(4):301-18. PubMed ID: 7813219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
    Carol W; Klinger G; Jäger R; Kasch R; Brandstädt A
    Exp Clin Endocrinol; 1992; 99(1):12-7. PubMed ID: 1628691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives.
    Back DJ; Power J; Winkler U; Schindler AE; Daume E; Simon A; Neiss A; Hammerstein J
    Adv Contracept; 1993 Dec; 9(4):319-30. PubMed ID: 8147246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings.
    Jung-Hoffmann C; Kuhl H
    Contraception; 1990 Oct; 42(4):423-38. PubMed ID: 2147887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
    Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
    Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W; al-Yacoub G; Fuhrmeister A
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group.
    Bruni V; Croxatto H; De La Cruz J; Dhont M; Durlot F; Fernandes MT; Andrade RP; Weisberg E; Rhoa M
    Gynecol Endocrinol; 2000 Apr; 14(2):90-8. PubMed ID: 10836195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
    Back DJ; Grimmer SF; Shenoy N; Orme ML
    Contraception; 1987 Jun; 35(6):619-26. PubMed ID: 2959449
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical studies with a new, low-dose oral contraceptive combination, containing 0.150 mg desogestrel and 0.020 mg ethinylestradiol.
    Acta Obstet Gynecol Scand Suppl; 1987; 144():1-44. PubMed ID: 2964165
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism.
    Jung-Hoffman C; Kuhl H
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2183-97. PubMed ID: 2147819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of desogestrel and ethinylestradiol combination in normal and hyperandrogenic young girls: speculations on contraception in adolescence.
    Venturoli S; Porcu E; Gammi L; Fabbri R; Paradisi R; Flamigni C; Patrono D; Capelli M; Paoletti C
    Acta Eur Fertil; 1988; 19(3):129-34. PubMed ID: 2976224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Laboratory and clinical study with a new progestagen combined with ethinyl estradiol used in contraception].
    Galán G; Gayán P; Tisné L
    Rev Chil Obstet Ginecol; 1985; 50(4):317-24. PubMed ID: 2953049
    [No Abstract]   [Full Text] [Related]  

  • 58. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
    Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth.
    Teichmann AT; Brill K; Albring M; Schnitker J; Wojtynek P; Kustra E
    Gynecol Endocrinol; 1995 Dec; 9(4):299-305. PubMed ID: 8629458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.